D3S-001 — Investigational Agent
KRAS Inhibitor · Phase 1 · D3 Bio (Wuxi)
Mechanism of Action
Next-generation oral covalent KRAS G12C inhibitor with rapid target engagement designed to more completely inhibit the cycling KRAS G12C protein, aiming for deeper and more durable pathway suppression than earlier G12C inhibitors.
Investigational Indications
- KRAS G12C-mutant non-small cell lung cancer
- KRAS G12C-mutant solid tumors